A second limitation is that we were unable to obtain data regarding the effectiveness of inhibiting IL7R signaling inhibitors in vivo with respect to restoring steroid sensitivity in primary leukemic cells, e.g., using patient-derived T-ALL xenograft mouse models. The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.